JOP20190279A1 - الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة - Google Patents

الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة

Info

Publication number
JOP20190279A1
JOP20190279A1 JOP/2019/0279A JOP20190279A JOP20190279A1 JO P20190279 A1 JOP20190279 A1 JO P20190279A1 JO P20190279 A JOP20190279 A JO P20190279A JO P20190279 A1 JOP20190279 A1 JO P20190279A1
Authority
JO
Jordan
Prior art keywords
crystalline forms
pyrazol
pyrimidin
bromo
amine
Prior art date
Application number
JOP/2019/0279A
Other languages
English (en)
Inventor
Kai Cui
Laria Julio Cesar Castro-Palomino
Weiyong Kong
Original Assignee
Novartis Ag
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Palobiofarma Sl filed Critical Novartis Ag
Publication of JOP20190279A1 publication Critical patent/JOP20190279A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

يتعلق هذا التطبيق بالعديد من الصور البلورية من 5-برومو -2، 6-داي (1H-بيرازول -1-يل) بيريميدين -4- أمين وملح منه، بالإضافة إلى تركيبات وطرق استخدامها. في بعض النماذج تحتوي الصور البلورية أيضا على الماء ("مركبات هيدرات"). هذه المواد مفيدة في علاج العديد من الأمراض، شاملة أمراض الكارسينوما، خصوصا سرطان الرئة وبشكل أكثر تحديدا سرطان خلايا الرئة الكبيرة.
JOP/2019/0279A 2017-05-31 2017-06-16 الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة JOP20190279A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2017086624 2017-05-31

Publications (1)

Publication Number Publication Date
JOP20190279A1 true JOP20190279A1 (ar) 2019-11-28

Family

ID=62778954

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0279A JOP20190279A1 (ar) 2017-05-31 2017-06-16 الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة

Country Status (17)

Country Link
US (2) US10933064B2 (ar)
EP (1) EP3630751B1 (ar)
JP (1) JP7273732B2 (ar)
KR (1) KR20200018503A (ar)
CN (1) CN110944995B (ar)
AR (1) AR111906A1 (ar)
AU (1) AU2018277241B2 (ar)
BR (1) BR112019025149A2 (ar)
CA (1) CA3065475A1 (ar)
CL (2) CL2019003468A1 (ar)
IL (2) IL270795B2 (ar)
JO (1) JOP20190279A1 (ar)
MX (1) MX2021014104A (ar)
RU (2) RU2019138329A (ar)
TW (1) TWI814725B (ar)
WO (1) WO2018220546A1 (ar)
ZA (1) ZA201907610B (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018007423A (es) * 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
JOP20190279A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
EP1261327B1 (en) * 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Adenosine receptor modulators
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
UA83101C2 (en) 2003-12-15 2008-06-10 Алмирал Аг 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
CN105315373B (zh) 2005-05-09 2018-11-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US20070208040A1 (en) * 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
US20080221103A1 (en) 2007-03-09 2008-09-11 Orchid Research Laboratories Ltd. New heterocyclic compounds
WO2008116186A1 (en) 2007-03-22 2008-09-25 Keck Graduate Institute Systems and devices for isothermal biochemical reactions and/or analysis
KR101562580B1 (ko) 2007-06-18 2015-10-22 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
WO2010027828A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
EP2342229A1 (en) 2008-09-12 2011-07-13 ISIS Innovation Limited Pd-1 specific antibodies and uses thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
SG196798A1 (en) 2008-12-09 2014-02-13 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
ES2669310T3 (es) 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
BR112013032552A2 (pt) 2011-07-24 2017-12-12 Curetech Ltd variantes de anticorpos monoclonais humanizados imunomoduladores
PT2785375T (pt) 2011-11-28 2020-10-29 Merck Patent Gmbh Anticorpos anti-pd-l1 e usos destes
PT2992017T (pt) 2013-05-02 2021-01-29 Anaptysbio Inc Anticorpos dirigidos contra a morte programada 1 (pd-1)
CA3175360A1 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
EP4130044A1 (en) 2013-09-13 2023-02-08 BeiGene Switzerland GmbH Anti-pd1 antibodies and their use as therapeutics and diagnostics
RS59480B1 (sr) 2013-12-12 2019-12-31 Shanghai hengrui pharmaceutical co ltd Pd-1 antitelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primena
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
PE20171067A1 (es) 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
KR102114562B1 (ko) * 2015-08-11 2020-05-26 노파르티스 아게 암의 치료에 사용하기 위한 5-브로모-2,6-디-(1h-피라졸-1-일)피리미딘-4-아민
EP3579874B1 (en) * 2017-02-10 2021-07-21 Novartis AG 1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
JOP20190279A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة

Also Published As

Publication number Publication date
RU2022102355A (ru) 2022-03-30
AU2018277241A1 (en) 2019-12-12
US20210145831A1 (en) 2021-05-20
IL270795B1 (en) 2023-08-01
CA3065475A1 (en) 2018-12-06
CL2019003468A1 (es) 2020-08-14
CN110944995A (zh) 2020-03-31
BR112019025149A2 (pt) 2020-06-23
KR20200018503A (ko) 2020-02-19
IL291721B1 (en) 2024-03-01
EP3630751B1 (en) 2024-03-27
IL270795B2 (en) 2023-12-01
US20200163963A1 (en) 2020-05-28
JP2020521774A (ja) 2020-07-27
JP7273732B2 (ja) 2023-05-15
CL2021002667A1 (es) 2022-07-01
MX2021014104A (es) 2021-12-10
RU2019138329A (ru) 2021-07-01
US11654144B2 (en) 2023-05-23
EP3630751A1 (en) 2020-04-08
AR111906A1 (es) 2019-08-28
US10933064B2 (en) 2021-03-02
IL270795A (en) 2020-01-30
ZA201907610B (en) 2021-10-27
AU2018277241B2 (en) 2021-03-04
CN110944995B (zh) 2024-03-12
IL291721A (en) 2022-05-01
RU2019138329A3 (ar) 2022-02-17
TW201920152A (zh) 2019-06-01
WO2018220546A1 (en) 2018-12-06
TWI814725B (zh) 2023-09-11

Similar Documents

Publication Publication Date Title
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
PH12016502168B1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PH12019501919A1 (en) Dioxolane analogues of uridine for the treatment of cancer
MX2010008040A (es) Derivados de pirimidina 5-fluoro como fungicidas.
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
MX2021002220A (es) Forma cristalina de base libre de lorlatinib.
MX2015016877A (es) Derivado de aminotriazina y composicion farmaceutica que comprende el mismo.
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MX2019009654A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
EP4183806A3 (en) Glycan-interacting compounds and methods of use
MX2016011898A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
TN2018000119A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
EA201000550A1 (ru) Производные тиазола
TW200700064A (en) Novel compounds
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
WO2018160879A3 (en) Macromolecular corrosion (mcin) inhibitors: structures, methods of making and using the same
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
PH12018500151A1 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
MX2021014104A (es) Formas cristalinas de 5-bromo-2,6-di(1 h-pirazol-1-il)pirimidin-4- amina y nuevas sales.
PH12020550127A1 (en) Modified nucleoside phosphoramidites
MX2020005251A (es) Composiciones para mejorar la funcionalidad de células car-t y uso de las mismas.
IN2015KN00569A (ar)